TFF Pharmaceuticals

TFF Pharmaceuticals, Inc. engages in the development and commercialization of drug products based on its patented Thin Film Freezing technology platform. It focuses on the manufacture of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company was founded on January 24, 2018 and is headquartered in Fort Worth, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Presentation will feature initial data from the Company's ongoing Phase 2 study of Tacrolimus Inhalation Powder (TFF TAC), which is being developed to prevent lung transplant rejection Presentation will feature initial data from the Company's ongoing Phase 2 study of Tacrolimus Inhalation Powder (TFF TAC), which is being developed to prevent lung transplant rejection

TFF Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for Presentation at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting

Treatment with TFF VORI resulted in positive treatment outcomes based on clinical, mycologic and radiologic responses while maintaining a favorable safety/tolerability profile, with no all-cause mortality, no invasive pulmonary aspergillosis (IPA)-related mortality, and no TFF VORI discontinuations  due to an adverse event (AE)

TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TAC

Company to host conference call and webcast on Tuesday, December 19th at 8:30 am ET Company to host conference call and webcast on Tuesday, December 19th at 8:30 am ET

TFF Pharmaceuticals to Host Webcast and Conference to Review Initial Data from the Ongoing Phase 2 Trials of TFF VORI and TFF TAC

Common Stock Will Begin Trading on a Split-Adjusted Basis on December 19, 2023 Common Stock Will Begin Trading on a Split-Adjusted Basis on December 19, 2023

TFF Pharmaceuticals Announces Reverse Stock Split

FORT WORTH, Texas, Dec. 13, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the appointment of Thomas B. King to its Board of Directors.

TFF Pharmaceuticals Appoints Thomas B. King to Board of Directors

FORT WORTH, Texas, Nov. 30, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that Catherine Lee, J.D. has been appointed to its Board of Directors.

TFF Pharmaceuticals Appoints Catherine Lee, J.D. to Board of Directors

FORT WORTH, Texas, Nov. 30, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the appointment of Michael Patane, Ph.D., to its Board of Directors.

TFF Pharmaceuticals Appoints Michael Patane, Ph.D., to Board of Directors

FORT WORTH, Texas, Nov. 27, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that company management will be participating in the 2023 Benchmark Discovery One-on-One Investor Conference being held December 7, 2023 at the New York Athletic Club in New York City. The company has two products in Phase 2 development and continues to guide for a December release of interim data from both studies.

TFF Pharmaceuticals to Participate in the 2023 Benchmark Discovery One-on-One Investor Conference – December 7, 2023

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Corey Davis - IR, LifeSci Advisors Harlan Weisman - CEO Zamaneh Mikhak - Chief Medical Officer Kirk Coleman - CFO Conference Call Participants Jonathan Aschoff - ROTH MKM Justin Walsh - JonesTrading Daniel Carlson - Tailwinds Operator Good afternoon, ladies and gentlemen, and welcome to the TFF Pharmaceuticals Third Quarter 2023 Corporate Update and Earnings Conference Call. As a reminder, this conference is being recorded.

TFF Pharmaceuticals, Inc. (TFFP) Q3 2023 Earnings Call Transcript

Company remains on track to report initial data from TFF VORI and TFF TAC Phase 2 trials by the end of 2023 Conference call and webcast, today Tuesday November 14, 2023, at 4:30 pm ET to provide overview of expected data readouts from ongoing Phase 2 studies FORT WORTH, Texas, Nov. 14, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported financial results for the third quarter of 2023 and provided a corporate update. “Based on the considerable progress that we have achieved over the last several months, we continue to expect initial data from our ongoing Phase 2 trials of TFF VORI and TFF TAC by year-end,” said Dr. Harlan Weisman, Chief Executive Officer of TFF Pharmaceuticals.

TFF Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Research shows the Company's Thin Film Freezing can reformulate broad range of monoclonal antibodies in combination with Aptar Pharma's Unidose (UDS) Powder Nasal Spray System for intranasal delivery Research shows the Company's Thin Film Freezing can reformulate broad range of monoclonal antibodies in combination with Aptar Pharma's Unidose (UDS) Powder Nasal Spray System for intranasal delivery

TFF Pharmaceuticals Announces Publication of Data Demonstrating Feasibility of Intranasal Delivery of Monoclonal Antibodies with Thin Film Freezing

Company to hold conference call and webcast on November 14, 2023, at 4:30 PM ET Company to hold conference call and webcast on November 14, 2023, at 4:30 PM ET

TFF Pharmaceuticals to Hold Third Quarter 2023 Financial and Business Results Conference Call on November 14, 2023

FORT WORTH, Texas, Oct. 02, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, would like to congratulate Drew Weissman, M.D., Ph.D., a member of the Company's Scientific Advisory Board, for receiving the Nobel Prize in Physiology or Medicine, based on his pioneering work enabling the development of mRNA COVID-19 vaccines.

TFF Pharmaceuticals Congratulates our Scientific Advisory Board Member, Drew Weissman, M.D., Ph.D., for Receiving the Nobel Prize in Physiology or Medicine for his Pioneering Work Enabling the Development of mRNA COVID-19 Vaccines

FORT WORTH, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced that CEO Harlan Weisman, M.D. will attend and hold one-on-one investor meetings at the upcoming Jones Trading 2023 Healthcare Summit. Dr. Weisman will also present and hold one-on-one investor meetings at the upcoming Roth MKM 2023 Healthcare Opportunities Conference.

TFF Pharmaceuticals to Participate in Upcoming Investor Conferences

FORT WORTH, Texas, Aug. 23, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that CEO Harlan Weisman, M.D. will be presenting a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023. Company management will also be participating in one-on-one meetings during the conference.

TFF Pharmaceuticals to Participate in the H.C. Wainwright 25th Annual Global Investment Conference – September 11-13, 2023

FORT WORTH, Texas, Aug. 17, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the closing of its $5.7 million underwritten public offering of 22,880,400 shares of its common stock, including 2,984,400 shares of its common stock issued pursuant to the full exercise by the underwriter of its over-allotment option. The public offering price for each share of common stock was $0.25. All of the securities in the underwritten public offering were sold by the Company.

TFF Pharmaceuticals Announces Closing of $5.7 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option

Amarin Corporation Plc

Bioventus

CommScope Hld

1847 Holdings LLC

Gannett Co.

FiscalNote Holdings Inc

Precigen

The RealReal

Rackspace Technology, Inc.

Engaging in the world of low-cost stocks often referred to as penny stocks, is appealing to those looking to capitalize on the potential upsides of the stock market. These stocks, priced below $5, are known for their intrinsic risk.

10 Top Penny Stocks To Buy According To Insiders In August

Investing in penny stocks represents an enticing prospect for those seeking to leverage the stock market's potential gains. Characterized by an inherent risk and the promise of significant rewards, these under-$5 shares often become the subjects of speculation.

7 Penny Stocks To Buy According To Insiders In August

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP ) Q2 2023 Results Conference Call August 15, 2023 11:00 AM ET Company Participants Corey Davis - IR, LifeSci Advisors Dr. Harlan Weisman - CEO Dr. Zamaneh Mikhak - Chief Medical Officer Kirk Coleman - CFO Conference Call Participants Jonathan Aschoff - ROTH MKM Justin Walsh - JonesTrading Vernon Bernardino - H.C. Wainwright Daniel Carlson - Tailwinds Operator Good morning, ladies and gentlemen, and welcome to the TFF Pharmaceuticals Second Quarter 2023 Corporate Update and Earnings Conference Call.

TFF Pharmaceuticals, Inc. (TFFP) Q2 2023 Earnings Call Transcript

Penny stocks provide a captivating opportunity for those aiming to profit in the stock market. The intrinsic risk and potential rewards associated with these stocks often lead to intense speculation and a quest for remarkable profits.

4 Penny Stocks To Buy According To Insiders In August

FORT WORTH, Texas, Aug. 15, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported financial results for the second quarter of 2023 and provided a corporate update.

TFF Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

FORT WORTH, Texas, Aug. 15, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it has priced its underwritten public offering of 19,896,000 shares of its common stock at a public offering price of $0.25 per share. All of the securities in the underwritten public offering are to be sold by the Company. The Company expects the gross proceeds from this offering to be approximately $4.97 million, before deducting the underwriting discount and other estimated offering expenses. The Company has granted the underwriter a 30-day option to purchase up to 2,984,400 additional shares of common stock. The Company expects to close the offering, subject to customary conditions, on August 17, 2023.

TFF Pharmaceuticals Prices $5 Million Public Offering of Common Stock

FORT WORTH, Texas, Aug. 14, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares of common stock in the underwritten public offering are to be sold by the Company. The Company also expects to grant the underwriters a 30-day option to purchase additional shares of common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

TFF Pharmaceuticals Announces Proposed Public Offering of Common Stock

Company to hold conference call and webcast on August 15, 2023, at 11:00 AM ET Company to hold conference call and webcast on August 15, 2023, at 11:00 AM ET

TFF Pharmaceuticals to Hold Second Quarter 2023 Financial and Business Results Conference Call on August 15, 2023

DUBLIN, Ireland and FORT WORTH, Texas, July 31, 2023 (GLOBE NEWSWIRE) -- Uniphar Durbin Ireland Limited (“Durbin” or the “Company”), a part of Uniphar Group's Product Access Division and a leading specialist in the international distribution of specialized pharmaceuticals, and TFF Pharmaceuticals, Inc. (Nasdaq: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the opening of an Expanded Access Program (EAP) enabling patients access to TFF-VORI in the United States, Australia, United Kingdom, Canada and select countries in Europe.

TFF Pharmaceuticals Inc. and Uniphar Durbin Ireland Ltd. Announce the Opening of an Expanded Access Program for Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Pulmonary Aspergillosis and Other Voriconazole Responsive Fungal Pulmonary Infec

News for TFF Pharmaceuticals Stock (TFFP)